Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol

BACKGROUND: Diffuse interstitial myocardial fibrosis is a key common pathological manifestation in hypertensive heart disease (HHD) progressing to heart failure (HF). Angiotensin receptor–neprilysin inhibitors (ARNi), now a front-line treatment for HF, confer benefits independent of blood pressure,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Vivian, Zheng, Qishi, Toh, Desiree-Faye, Pua, Chee Jian, Bryant, Jennifer A., Lee, Chi-Hang, Cook, Stuart A., Butler, Javed, Díez, Javier, Richards, A. Mark, Le, Thu-Thao, Chin, Calvin W. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478086/
https://www.ncbi.nlm.nih.gov/pubmed/37674806
http://dx.doi.org/10.3389/fcvm.2023.1248468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478086/
https://www.ncbi.nlm.nih.gov/pubmed/37674806
http://dx.doi.org/10.3389/fcvm.2023.1248468

Ejemplares similares